NEOS Investment Management LLC Has $331,000 Stake in Arcus Biosciences, Inc. (NYSE:RCUS)

NEOS Investment Management LLC lessened its position in Arcus Biosciences, Inc. (NYSE:RCUS) by 39.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,233 shares of the company’s stock after selling 14,705 shares during the period. NEOS Investment Management LLC’s holdings in Arcus Biosciences were worth $331,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of RCUS. R Squared Ltd acquired a new position in shares of Arcus Biosciences during the fourth quarter worth $26,000. Point72 Hong Kong Ltd bought a new position in Arcus Biosciences during the 3rd quarter worth $47,000. US Bancorp DE lifted its holdings in Arcus Biosciences by 2,432.0% during the 4th quarter. US Bancorp DE now owns 6,887 shares of the company’s stock worth $103,000 after buying an additional 6,615 shares during the period. AXQ Capital LP bought a new stake in shares of Arcus Biosciences in the 4th quarter valued at about $160,000. Finally, KLP Kapitalforvaltning AS acquired a new stake in shares of Arcus Biosciences in the fourth quarter valued at about $207,000. 92.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. HC Wainwright raised Arcus Biosciences from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $18.00 to $24.00 in a research note on Wednesday, February 26th. Morgan Stanley reduced their price objective on shares of Arcus Biosciences from $36.00 to $25.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 18th. Finally, Bank of America decreased their price objective on shares of Arcus Biosciences from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Wednesday, February 19th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $30.25.

Insider Buying and Selling

In related news, CEO Terry J. Rosen acquired 19,800 shares of the stock in a transaction dated Thursday, February 27th. The stock was purchased at an average cost of $10.18 per share, with a total value of $201,564.00. Following the completion of the purchase, the chief executive officer now directly owns 2,554,160 shares in the company, valued at $26,001,348.80. This trade represents a 0.78 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Yasunori Kaneko bought 20,000 shares of the business’s stock in a transaction that occurred on Thursday, February 27th. The shares were bought at an average cost of $10.06 per share, for a total transaction of $201,200.00. Following the transaction, the director now owns 28,400 shares of the company’s stock, valued at $285,704. The trade was a 238.10 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is owned by company insiders.

Arcus Biosciences Trading Down 3.7 %

RCUS opened at $7.87 on Tuesday. The company has a fifty day moving average price of $10.99 and a two-hundred day moving average price of $14.25. Arcus Biosciences, Inc. has a 1-year low of $7.56 and a 1-year high of $18.98. The company has a market cap of $827.02 million, a P/E ratio of -2.50 and a beta of 1.36. The company has a current ratio of 5.24, a quick ratio of 5.24 and a debt-to-equity ratio of 0.08.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($1.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.17) by $0.14. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The business had revenue of $36.00 million for the quarter, compared to the consensus estimate of $29.38 million. Analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.